Patient‐derived renal cell carcinoma organoids for personalized cancer therapy
Clinical and Translational Medicine2022Vol. 12(7), pp. e970–e970
Citations Over TimeTop 10% of 2022 papers
Zhichao Li, Haibo Xu, Lei Yu, Jia Wang, Qian Meng, Hongbing Mei, Zhiming Cai, Wei Chen, Weiren Huang
Abstract
Patient-derived RCC organoids are valuable pre-clinical models for academic research and personalized medicine.
Related Papers
- → Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients(2016)86 cited
- → Accuracy of Fine Needle Aspiration in Distinguishing Subtypes of Renal Cell Carcinoma(1997)107 cited
- → Papillary renal cell carcinoma: clinicopathological characteristics and evaluation of prognosis in 42 patients(1999)57 cited
- → Clear Cell Papillary Renal Cell Carcinoma: A Rare Subtype(2011)1 cited
- Clinicopathological features of renal cell tumor: an analysis of 229 cases(2006)